ERBB2 and breast carcinoma: The study showed that SMART-Exos loaded with anti-CD3-antiHER2 dual scFv antibodies concurrently recognized T cell surface CD3 and HER2 overexpressed by breast cancer cells, and promoted anticancer immunity in a specific and controlled way [83].